Clinical data | |
---|---|
Trade names | Milgamma |
Other names | S-Benzoylthiamine O-monophosphate |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.040.906 |
Chemical and physical data | |
Formula | C19H23N4O6PS |
Molar mass | 466.45 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Benfotiamine (rINN, or S-benzoylthiamine O-monophosphate) is a synthetic, fat-soluble, S-acyl derivative of thiamine (vitamin B1) that is approved in some countries as a medication or dietary supplement to treat diabetic sensorimotor polyneuropathy. Benfotiamine was developed in late 1950s in Japan.[1][2]